scholarly journals Effect of Vitamin E Supplementation on Plasma Nitric Oxide in Menopausal Women with Hot Flashes: A Cross-Over, Randomized Clinical Trial

2018 ◽  
Vol 20 (9) ◽  
Author(s):  
Parvaneh Rezasoltani ◽  
Nahid Elliyoun ◽  
Tahereh Ziaie ◽  
Ehsan Kazemnezhad Leyli ◽  
Soudabeh Kazemi Aski ◽  
...  
2019 ◽  
Vol 44 ◽  
pp. 166-173 ◽  
Author(s):  
Rahele Kargozar ◽  
Roshanak Salari ◽  
Lida Jarahi ◽  
Mahdi Yousefi ◽  
Seyedeh Azam Pourhoseini ◽  
...  

2014 ◽  
Vol 28 (3) ◽  
pp. 266-274 ◽  
Author(s):  
Rachel M. Slaton ◽  
Megan N. Champion ◽  
Kayla B. Palmore

Background: Studies in recent years have exposed concerns about the safety of hormone replacement therapy (HRT) in the treatment of vasomotor symptoms (VMS) in menopausal women. Numerous studies have examined the use of antidepressants for relief of VMS. Despite recommendations to deny approval of paroxetine mesylate (Brisdelle™) for the treatment of VMS, the Food and Drug Administration (FDA) recently granted it approval for this indication. Objective: To evaluate all published literature examining use of paroxetine salts (mesylate and hydrochloride) in the treatment of menopausal VMS. Methods: Both PubMed and International Pharmaceutical Abstracts (IPA) were searched using the keywords hot flashes, vasomotor symptoms, menopause, and paroxetine. In PubMed, MeSH terms were used for paroxetine, menopause, and hot flashes. Searches were limited to humans, English language, and clinical trial design. The references for each study identified in this search process were examined in order to locate any additional relevant articles. Results: Compared with placebo, paroxetine salts offer a modest benefit in the treatment of menopausal VMS reducing the frequency and severity of weekly hot flashes. Conclusion: Paroxetine (mesylate or hydrochloride) is an effective alternative to HRT for the reduction in VMS in menopausal women. Future head-to-head studies with active medications are needed in order to identify the best algorithm of treatment for this condition.


Author(s):  
Shima Afshar ◽  
Fariba Afshar ◽  
Amir Rezazade ◽  
Zeinab Shaker Ardakani ◽  
Zahra Jafari Azar ◽  
...  

Background: Menopause is a critical period with frequent sexual disorders. Objectives: The current study assessed the therapeutic effect of a combination of the aerial part of Melissa officinalis, fennel fruit extract, and Nigella sativa seed powder on the sexual dysfunction of postmenopausal women. Methods: This randomized clinical trial was performed on 48 menopausal women from April 2015 to October 2017. The participants included the menopausal women referring to the clinic of Gorgan health centers aged between 41 and 54 years with natural menopause (amenorrhea for at least 12 months) and discomfort in sexual activity. They were randomized into two treatment groups. Group 1 (n = 27) received 1000 mg capsules (Melissa officinalis, fennel extract, and Nigella sativa powder), and group 2 (n = 21) received a placebo (1000 mg starch capsules (in an eight-week course of treatment (one capsule per day for each group). The variables in the female sexual function index (FSFI) questionnaire were compared in the two groups before and after the intervention. Results: The results showed that the mean scores of sexual dysfunction in the domains of arousal, lubrication, orgasm, satisfaction, and pain were not significantly different between the two groups (P > 0.05). Conclusions: Despite many studies on the effectiveness of Melissa, Foenculum, and Nigella, this study showed that a combination of Foeniculum vulgare, Melissa officinalis extract, and Nigella sativa seed powder does not improve the sexual function of postmenopausal women with sexual dysfunction, and it might be the synergism effect of this combination.


Sign in / Sign up

Export Citation Format

Share Document